信迪利单抗联合化疗方案对小细胞肺癌患者生活质量及免疫功能的影响

Sintilimab Combined with Chemotherapy for the Quality of Life of Patients with Small Cell Lung Cancer The Impact of Immune Function

目的探讨信迪利单抗联合化疗方案对小细胞肺癌(SCLC)患者生活质量及免疫功能的影响。方法选择2019年1月至2020年12月我院收治的SCLC患者84例,采用随机数字表法分为两组,各42例。对照组进行常规化疗方案,在对照组基础上,观察组加用信迪利单抗,连续使用4个周期。比较两组生活质量、免疫功能及药物安全性。结果两组治疗前生活质量、免疫功能比较,差异无统计学意义(P>0.05);治疗后,观察组生活质量评分、CD4+、CD4+/CD8+高于对照组,CD8+低于对照组,差异有统计学意义(P<0.05);两组均未发生严重不良反应。结论在SCLC患者中采用信迪利单抗联合化疗方案,利于改善患者免疫功能,提高生活质量,且不会增加不良反应,临床应用安全可靠。

Objective To investigate the effect of sintilimab combined with chemotherapy on the quality of life and immune function of patients with small cell lung cancer(SCLC).Methods A total of 84 SCLC patients admitted to our hospital from January 2019 to December 2020 were selected and divided into two groups by random number table,with 42 cases in each group.The control group received conventional chemotherapy.On the basis of the control group,the observation group was added with Sintilizumab for 4 consecutive cycles.The quality of life,immune function and drug safety were compared between the two groups.Results There was no significant difference in the quality of life and immune function between the two groups before treatment(P>0.05);after treatment,the quality of life score,CD4+,CD4+/CD8+ in the observation group were higher than those in the control group,and CD8+ was lower than the control group.Statistically significant(P<0.05);no serious adverse reactions occurred in the two groups.Conclusion The use of sintilimab combined with chemotherapy in SCLC patients is beneficial to improve the immune function of patients and improve the quality of life without increasing adverse reactions.The clinical application is safe and reliable.